CervoMed Inc. (BST:DP8)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.67M -60.3% |
| Revenue (ttm) | 289.98K -95.7% |
| Net Income | -26.57M |
| EPS | -2.85 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.530 |
| Previous Close | 1.540 |
| Day's Range | 1.430 - 1.560 |
| 52-Week Range | 1.430 - 8.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant... [Read more]
Financial Performance
In 2025, CervoMed's revenue was $4.01 million, a decrease of -58.86% compared to the previous year's $9.74 million. Losses were -$26.97 million, 65.5% more than in 2024.
Financial numbers in USD Financial StatementsNews
CervoMed announces publication of two articles supporting neflamapimod
CervoMed (CRVO) announced that results from the placebo-controlled phase of the Phase 2b RewinD-LB clinical trial of neflamapimod in dementia with Lewy bodies, or DLB, have been published in Alzheimer...
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer's Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DL...
CervoMed presents initial data from neflamapimod trial
CervoMed (CRVO) announced initial data showing a reduction in mean plasma levels of neurofilament light chain, or NfL, a key biomarker of neuronal damage and degeneration, over the first 12…
CervoMed neflamapimod update removes key overhang, says Jones
Jones analyst Boris Peaker says CervoMed (CRVO) announced this morning that the FDA removed neflamapimod’s prior drug exposure limit, allowing the company to advance higher dose levels. The update rem...
CervoMed announces PK results with new neflamapimod oral tablet formula
CervoMed (CRVO) announced pharmacokinetic, PK, regulatory, and manufacturing advances that enable a higher-dose, twice-daily oral regimen of neflamapimod in future clinical trials. The developments in...
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today...
CervoMed Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Major progress was reported in the clinical development of neflamapimod for dementia with Lewy bodies, with replicated phase 2 data, regulatory alignment for phase III, and a new stable formulation. Efficacy is linked to achieving target drug concentrations, and broader applications are being explored.
CervoMed Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Neflamapimod is advancing as a targeted therapy for DLB, with positive phase II data, a clear phase III path, and expansion into PPA and ALS. Key near-term milestones include strategic partnership, phase III initiation, and clinical data readouts in PPA and ALS.
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
CervoMed to Participate in September Investor Conferences
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), tod...
CervoMed price target lowered to $7 from $9 at Roth Capital
Roth Capital lowered the firm’s price target on CervoMed (CRVO) to $7 from $9 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
CervoMed Transcript: Canaccord Genuity's 46th Annual Growth Conference
Significant clinical and regulatory progress was reported for a phase III-ready DLB drug, with new data supporting its targeted mechanism and clinical efficacy. Expansion into PPA and ALS indications is underway, with key biomarker and trial milestones expected later this year.
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingd...
CervoMed price target lowered to $18 from $27 at Canaccord
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on CervoMed (CRVO) to $18 from $27 and keeps a Buy rating on the shares. The firm said they continue to…
CervoMed Quarterly report: Q2 2026
CervoMed has published its Q2 2026 quarterly earnings report on August 7, 2026.
CervoMed Earnings release: Q2 2026
CervoMed released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CervoMed completes enrollment in neflamapimod study
CervoMed (CRVO) announced that it has completed enrollment in the Phase 2a study of neflamapimod for the treatment of nfvPPA, a type of FTD. Interim biomarker data from the study…
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
CervoMed registers to sell 10.08M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 10.08M shares of common stock. The company is not selling any…
CervoMed Registration statement: Registration filing
CervoMed filed a registration statement on July 6, 2026, providing details about a securities offering with the SEC.
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain at...